| scholarly article | Q13442814 |
| P2093 | author name string | Hossein Jadvar | |
| P2860 | cites work | Androgen deprivation therapy influences the uptake of 11C-choline in patients with recurrent prostate cancer: the preliminary results of a sequential PET/CT study | Q56984031 |
| Transport mechanisms of trans-1-amino-3-fluoro[1-14C]cyclobutanecarboxylic acid in prostate cancer cells | Q57759278 | ||
| Fluorine-18-labeled androgens: radiochemical synthesis and tissue distribution studies on six fluorine-substituted androgens, potential imaging agents for prostatic cancer | Q68101526 | ||
| Androgen Control of Mitochondrial and Nuclear DNA Synthesis in Male Sex Accessory Tissue of Castrate Rats1 | Q70358411 | ||
| Analysis of 2-carbon-11-thymidine blood metabolites in PET imaging | Q71152335 | ||
| Experience with carbon-11 choline positron emission tomography in prostate carcinoma | Q73010182 | ||
| Sensitivity in detecting osseous lesions depends on anatomic localization: planar bone scintigraphy versus 18F PET | Q73081517 | ||
| The increased accumulation of [18F]fluorodeoxyglucose in untreated prostate cancer | Q73559459 | ||
| Radiosynthesis of 3'-deoxy-3'-[(18)F]fluorothymidine: [(18)F]FLT for imaging of cellular proliferation in vivo | Q73694089 | ||
| Carbon-11-thymidine and FDG to measure therapy response | Q77425014 | ||
| Differential Metabolism and Pharmacokinetics of ?-[1-11C]-Methionine and 2-[18F] Fluoro-2-deoxy-?-glucose (FDG) in Androgen Independent Prostate Cancer | Q79095673 | ||
| Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in | Q79557156 | ||
| Synthesis of 7alpha-(fluoromethyl)dihydrotestosterone and 7alpha-(fluoromethyl)nortestosterone, structurally paired androgens designed to probe the role of sex hormone binding globulin in imaging androgen receptors in prostate tumors by positron emi | Q80514624 | ||
| Evaluation of [11C]-choline positron-emission/computed tomography in patients with increasing prostate-specific antigen levels after primary treatment for prostate cancer | Q81151106 | ||
| Influence of PSA, PSA velocity and PSA doubling time on contrast-enhanced 18F-choline PET/CT detection rate in patients with rising PSA after radical prostatectomy | Q83199552 | ||
| Positron emission tomography with C11-acetate for tumor detection and localization in patients with prostate-specific antigen relapse after radical prostatectomy | Q83336274 | ||
| Superscan pattern of F-18 sodium fluoride PET/CT study in a case of prostate cancer | Q85047522 | ||
| Choline Kinase: An Important Target for Cancer | Q21128635 | ||
| Positron emission tomography imaging of prostate cancer | Q24596241 | ||
| Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study | Q24596926 | ||
| Targeting the internal epitope of prostate-specific membrane antigen with 89Zr-7E11 immuno-PET | Q24633858 | ||
| Adenovirus-mediated gene expression imaging to directly detect sentinel lymph node metastasis of prostate cancer | Q30492895 | ||
| Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer. | Q31982942 | ||
| Restricted water diffusibility as measured by diffusion-weighted MR imaging and choline uptake in (11)C-choline PET/CT are correlated in pelvic lymph nodes in patients with prostate cancer | Q33583831 | ||
| Titration of variant HSV1-tk gene expression to determine the sensitivity of 18F-FHBG PET imaging in a prostate tumor | Q33585439 | ||
| Optimization of adenoviral vectors to direct highly amplified prostate-specific expression for imaging and gene therapy | Q33647321 | ||
| Functionality of androgen receptor-based gene expression imaging in hormone refractory prostate cancer | Q33650205 | ||
| The role of the androgen receptor in the development and progression of prostate cancer | Q33730911 | ||
| Capromab Pendetide imaging of prostate cancer | Q33913721 | ||
| Two-step transcriptional amplification as a method for imaging reporter gene expression using weak promoters | Q33952065 | ||
| Mammalian hexokinases and their abnormal expression in cancer | Q33981838 | ||
| Skeletal PET with 18F-fluoride: applying new technology to an old tracer. | Q34008718 | ||
| Quantitative PET imaging of tumor integrin alphavbeta3 expression with 18F-FRGD2. | Q34159304 | ||
| 89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo. | Q34389457 | ||
| Prostate cancer: PET with 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline | Q34448553 | ||
| Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference | Q34541651 | ||
| Value of 11C-choline PET and PET/CT in patients with suspected prostate cancer | Q34570356 | ||
| Detection of lymph-node metastases with integrated [11C]choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: results confirmed by open pelvic-retroperitoneal lymphadenectomy | Q34614216 | ||
| [11C]choline PET/CT imaging in occult local relapse of prostate cancer after radical prostatectomy | Q34683467 | ||
| The role of DNA synthesis imaging in cancer in the era of targeted therapeutics | Q34907192 | ||
| F-Labeled GRPR Agonists and Antagonists: A Comparative Study in Prostate Cancer Imaging | Q34912606 | ||
| In vitro and in vivo evaluation of 64Cu-labeled SarAr-bombesin analogs in gastrin-releasing peptide receptor-expressing prostate cancer | Q34942281 | ||
| Detection of recurrent prostate carcinoma with anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid PET/CT and 111In-capromab pendetide SPECT/CT | Q34995973 | ||
| Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen | Q35035214 | ||
| Molecular Mechanisms of Bone 18F-NaF Deposition | Q35203602 | ||
| Androgen-independent molecular imaging vectors to detect castration-resistant and metastatic prostate cancer | Q35256725 | ||
| 18F-fluoride PET: changes in uptake as a method to assess response in bone metastases from castrate-resistant prostate cancer patients treated with 223Ra-chloride (Alpharadin) | Q35335407 | ||
| Modern Detection of Prostate Cancer's Bone Metastasis: Is the Bone Scan Era Over? | Q35372874 | ||
| Molecular imaging in prostate cancer. | Q35549460 | ||
| Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. | Q35897181 | ||
| PET: a revolution in medical imaging | Q35920182 | ||
| In vitro and in vivo evaluation of a 64Cu-labeled NOTA-Bn-SCN-Aoc-bombesin analogue in gastrin-releasing peptide receptor expressing prostate cancer | Q35925945 | ||
| PET and prostate cancer | Q35926932 | ||
| PET imaging of cellular proliferation | Q36031444 | ||
| Prospective evaluation of 18F-NaF and 18F-FDG PET/CT in detection of occult metastatic disease in biochemical recurrence of prostate cancer | Q36033412 | ||
| PET/CT Imaging and Radioimmunotherapy of Prostate Cancer | Q36085426 | ||
| Prostate specific membrane antigen- a target for imaging and therapy with radionuclides. | Q36135685 | ||
| Developing imaging strategies for castration resistant prostate cancer | Q36152211 | ||
| [18F]-2'-Fluoro-5-methyl-1-beta-D-arabinofuranosyluracil (18F-FMAU) in prostate cancer: initial preclinical observations. | Q36236041 | ||
| Positron emission tomography measurement of tumor metabolism and growth: its expanding role in oncology | Q36420719 | ||
| Fatty acid oxidation is a dominant bioenergetic pathway in prostate cancer | Q36472442 | ||
| Assessment of an 18F-labeled phosphoramidate peptidomimetic as a new prostate-specific membrane antigen-targeted imaging agent for prostate cancer. | Q36619673 | ||
| Adaptive landscapes and emergent phenotypes: why do cancers have high glycolysis? | Q36877059 | ||
| Choline autoradiography of human prostate cancer xenograft: effect of castration | Q37052606 | ||
| [F-18]-fluorodeoxyglucose PET-CT of the normal prostate gland | Q37085677 | ||
| Engineered humanized diabodies for microPET imaging of prostate stem cell antigen-expressing tumors | Q37101581 | ||
| Registration methodology for histological sections and in vivo imaging of human prostate | Q37105128 | ||
| Causes and consequences of increased glucose metabolism of cancers | Q37181519 | ||
| Imaging of cell proliferation: status and prospects | Q37181529 | ||
| Humanized radioiodinated minibody for imaging of prostate stem cell antigen-expressing tumors | Q37289040 | ||
| Tracking cellular stress with labeled FMAU reflects changes in mitochondrial TK2. | Q37306005 | ||
| Nuclear imaging of prostate cancer with gastrin-releasing-peptide-receptor targeted radiopharmaceuticals | Q37320510 | ||
| Novel tracers and their development for the imaging of metastatic prostate cancer | Q37321810 | ||
| Molecular imaging of prostate cancer with 18F-fluorodeoxyglucose PET. | Q37325974 | ||
| Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate cancer | Q37335448 | ||
| Examining the relationship between Cu-ATSM hypoxia selectivity and fatty acid synthase expression in human prostate cancer cell lines. | Q37414432 | ||
| PET-CT for treatment planning in prostate cancer | Q37417102 | ||
| Pharmacokinetic assessment of the uptake of 16beta-18F-fluoro-5alpha-dihydrotestosterone (FDHT) in prostate tumors as measured by PET. | Q40421840 | ||
| Investigation on tumor hypoxia in resectable primary prostate cancer as demonstrated by 18F-FAZA PET/CT utilizing multimodality fusion techniques | Q40445567 | ||
| Expression of glucose transporter 1 (Glut-1) in cell lines and clinical specimens from human prostate adenocarcinoma. | Q40497818 | ||
| Pharmacokinetics of the thymidine analog 2'-fluoro-5-methyl-1-beta-D-arabinofuranosyluracil (FMAU) in tumor-bearing rats | Q40565398 | ||
| Monitoring of therapy in androgen-dependent prostate tumor model by measuring tumor proliferation. | Q40582151 | ||
| Characterization of acetate metabolism in tumor cells in relation to cell proliferation: acetate metabolism in tumor cells. | Q40813713 | ||
| [(11)C]FMAU and [(18)F]FHPG as PET tracers for herpes simplex virus thymidine kinase enzyme activity and human cytomegalovirus infections | Q40885241 | ||
| Androgen receptor gene mutations in prostate cancer. Implications for disease progression and therapy | Q41140164 | ||
| The androgen receptor in prostate cancer | Q41176337 | ||
| Phase I trial of 1-(2'-deoxy-2'-fluoro-1-beta-D-arabinofuranosyl)-5-methyluracil (FMAU). | Q41405949 | ||
| Pharmacokinetics of the thymidine analog 2'-fluoro-5-[(14)C]-methyl-1-beta-D-arabinofuranosyluracil ([(14)C]FMAU) in rat prostate tumor cells | Q41754690 | ||
| N-[N-[(S)-1,3-Dicarboxypropyl]carbamoyl]-4-[18F]fluorobenzyl-L-cysteine, [18F]DCFBC: a new imaging probe for prostate cancer | Q41913170 | ||
| Prognostic value of baseline [18F] fluorodeoxyglucose positron emission tomography and 99mTc-MDP bone scan in progressing metastatic prostate cancer | Q42071725 | ||
| Significance of incidental focal uptake in prostate on 18-fluoro-2-deoxyglucose positron emission tomography CT images | Q42125168 | ||
| Cellular distribution of Glut-1 and Glut-5 in benign and malignant human prostate tissue | Q42494827 | ||
| C11-acetate and F-18 FDG PET for men with prostate cancer bone metastases: relative findings and response to therapy | Q42786749 | ||
| Optimization, biological evaluation and microPET imaging of copper-64-labeled bombesin agonists, [64Cu-NO2A-(X)-BBN(7–14)NH2], in a prostate tumor xenografted mouse model | Q42876685 | ||
| [11C]choline positron emission tomography/computerized tomography to restage prostate cancer cases with biochemical failure after radical prostatectomy and no disease evidence on conventional imaging | Q42965590 | ||
| 18F-fluoride uptake in bone metastasis: morphologic and metabolic analysis on integrated PET/CT. | Q43120299 | ||
| Influence of trigger PSA and PSA kinetics on 11C-Choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy | Q43290085 | ||
| Synthesis and evaluation of 2'-deoxy-2'-18F-fluoro-5-fluoro-1-beta-D-arabinofuranosyluracil as a potential PET imaging agent for suicide gene expression. | Q43500558 | ||
| FDG PET for evaluating the change of glucose metabolism in prostate cancer after androgen ablation. | Q43707212 | ||
| Visualization of advanced human prostate cancer lesions in living mice by a targeted gene transfer vector and optical imaging | Q43787639 | ||
| Combined 18F-FDG and 11C-methionine PET scans in patients with newly progressive metastatic prostate cancer. | Q43860785 | ||
| 11C-acetate PET imaging of prostate cancer. | Q43890716 | ||
| Radiolabeled 2'-fluorodeoxyuracil-beta-D-arabinofuranoside (FAU) and 2'-fluoro-5-methyldeoxyuracil-beta -D-arabinofuranoside (FMAU) as tumor-imaging agents in mice | Q43971568 | ||
| Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer | Q44006461 | ||
| Comparison of [18 F]fluorocholine and [18 F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer | Q44018418 | ||
| Carbon-11 acetate positron emission tomography can detect local recurrence of prostate cancer | Q44149788 | ||
| Accumulation of [11C]acetate in normal prostate and benign prostatic hyperplasia: comparison with prostate cancer | Q44192340 | ||
| Investigations with FDG-PET scanning in prostate cancer show limited value for clinical practice | Q44223244 | ||
| Intraindividual comparison of [11C]acetate and [11C]choline PET for detection of metastases of prostate cancer | Q44325029 | ||
| 11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse | Q44392802 | ||
| Detecting Metastatic Pelvic Lymph Nodes by <sup>18</sup>F-2-Deoxyglucose Positron Emission Tomography in Patients with Prostate-Specific Antigen Relapse after Treatment for Localized Prostate Cancer | Q44436488 | ||
| Synthesis of 2'-deoxy-2'-[18F]fluoro-beta-D-arabinofuranosyl nucleosides, [18F]FAU, [18F]FMAU, [18F]FBAU and [18F]FIAU, as potential PET agents for imaging cellular proliferation. Synthesis of [18F]labelled FAU, FMAU, FBAU, FIAU. | Q44439632 | ||
| Evaluation of 2'-deoxy-2'-flouro-5-methyl-1-beta-D-arabinofuranosyluracil as a potential gene imaging agent for HSV-tk expression in vivo | Q44551092 | ||
| Increased fatty acid synthase expression and activity during progression of prostate cancer in the TRAMP model | Q44601579 | ||
| Kinetics of 3′-Deoxy-3′-[F-18]Fluorothymidine Uptake and Retention in Dogs | Q44612239 | ||
| Prognostic value of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography imaging for patients with prostate cancer | Q44612245 | ||
| SNM Practice Guideline for Sodium 18F-Fluoride PET/CT Bone Scans 1.0 | Q44635267 | ||
| Imaging of prostate cancer metastases with 18F-fluoroacetate using PET/CT. | Q44777793 | ||
| Tumor localization of 16beta-18F-fluoro-5alpha-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer | Q44787047 | ||
| Highly efficient automated synthesis of [(11)C]choline for multi dose utilization | Q44863225 | ||
| Relationship between cancer type and impact of PET and PET/CT on intended management: findings of the national oncologic PET registry | Q44942846 | ||
| Radiation dose estimates in humans for (11)C-acetate whole-body PET. | Q44964634 | ||
| Direct comparison of radiolabeled probes FMAU, FHBG, and FHPG as PET imaging agents for HSV1-tk expression in a human breast cancer model | Q45008590 | ||
| microPET and autoradiographic imaging of GRP receptor expression with 64Cu-DOTA-[Lys3]bombesin in human prostate adenocarcinoma xenografts. | Q45010334 | ||
| PET-based radiation dosimetry in man of 18F-fluorodihydrotestosterone, a new radiotracer for imaging prostate cancer | Q45144596 | ||
| Imaging DNA synthesis with [18F]FMAU and positron emission tomography in patients with cancer | Q45178853 | ||
| Detection of prostate cancer with 11C-methionine positron emission tomography | Q45183397 | ||
| Prostate cancer localization with 18fluorine fluorocholine positron emission tomography. | Q45183432 | ||
| Imaging DNA synthesis in vivo with 18F-FMAU and PET. | Q45254030 | ||
| Positron tomographic assessment of androgen receptors in prostatic carcinoma | Q45279143 | ||
| [11C]Choline PET/CT detection of bone metastases in patients with PSA progression after primary treatment for prostate cancer: comparison with bone scintigraphy | Q45330298 | ||
| Molecular engineering of a two-step transcription amplification (TSTA) system for transgene delivery in prostate cancer | Q45883742 | ||
| Dual tracer 11C-choline and FDG-PET in the diagnosis of biochemical prostate cancer relapse after radical treatment. | Q45959752 | ||
| Positron emission tomography/computed tomography and radioimmunotherapy of prostate cancer | Q37457888 | ||
| Prostate cancer: role of SPECT and PET in imaging bone metastases | Q37607846 | ||
| 18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients | Q37696901 | ||
| Radionuclide based imaging of prostate cancer | Q37768196 | ||
| The role of choline positron emission tomography/computed tomography in the management of patients with prostate-specific antigen progression after radical treatment of prostate cancer | Q37792304 | ||
| EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. | Q37840406 | ||
| The utility of 11C-choline PET/CT for imaging prostate cancer: a pictorial guide | Q37878758 | ||
| 18F-fluorocholine for prostate cancer imaging: a systematic review of the literature. | Q37918311 | ||
| End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice | Q37921009 | ||
| Novel molecular targets for the therapy of castration-resistant prostate cancer | Q37972448 | ||
| Putative transport mechanism and intracellular fate of trans-1-amino-3-18F-fluorocyclobutanecarboxylic acid in human prostate cancer | Q38335459 | ||
| In vivo imaging of intraprostatic-specific gene transcription by PET. | Q38431707 | ||
| 2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer | Q39449818 | ||
| Assessment of PET tracer uptake in hormone-independent and hormone-dependent xenograft prostate cancer mouse models | Q39486287 | ||
| Do androgens control the uptake of 18F-FDG, 11C-choline and 11C-acetate in human prostate cancer cell lines? | Q39512219 | ||
| Micro-PET/CT monitoring of herpes thymidine kinase suicide gene therapy in a prostate cancer xenograft: the advantage of a cell-specific transcriptional targeting approach. | Q39516198 | ||
| Gastrin-releasing peptide receptor-based targeting using bombesin analogues is superior to metabolism-based targeting using choline for in vivo imaging of human prostate cancer xenografts | Q39571686 | ||
| Design, synthesis and validation of integrin α2β1-targeted probe for microPET imaging of prostate cancer. | Q39586238 | ||
| 18F-labeled bombesin analog for specific and effective targeting of prostate tumors expressing gastrin-releasing peptide receptors. | Q39608200 | ||
| Early response assessment in prostate carcinoma by 18F-fluorothymidine following anticancer therapy with docetaxel using preclinical tumour models | Q39650275 | ||
| 11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer | Q39652684 | ||
| High-resolution animal PET imaging of prostate cancer xenografts with three different 64Cu-labeled antibodies against native cell-adherent PSMA. | Q39670891 | ||
| 68Ga-labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer | Q39689821 | ||
| An affinity matured minibody for PET imaging of prostate stem cell antigen (PSCA)-expressing tumors | Q39720680 | ||
| Case study of anti-1-amino-3-F-18 fluorocyclobutane-1-carboxylic acid (anti-[F-18] FACBC) to guide prostate cancer radiotherapy target design | Q39985462 | ||
| Configurations of a two-tiered amplified gene expression system in adenoviral vectors designed to improve the specificity of in vivo prostate cancer imaging. | Q40008139 | ||
| Characterization of osteolytic, osteoblastic, and mixed lesions in a prostate cancer mouse model using 18F-FDG and 18F-fluoride PET/CT | Q40011076 | ||
| Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET-CT: a comparative study | Q40094312 | ||
| In vivo evaluation and small-animal PET/CT of a prostate cancer mouse model using 64Cu bombesin analogs: side-by-side comparison of the CB-TE2A and DOTA chelation systems | Q40107074 | ||
| Targeting, imaging, and therapy using a humanized antiprostate stem cell antigen (PSCA) antibody | Q40141515 | ||
| 18F-Fluoride positron emission tomography and positron emission tomography/computed tomography | Q40166772 | ||
| Initial experience with the radiotracer anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma | Q40186415 | ||
| A preliminary study of anti-1-amino-3-18F-fluorocyclobutyl-1-carboxylic acid for the detection of prostate cancer | Q40186421 | ||
| Effect of hypoxia on the uptake of [methyl-3H]choline, [1-14C] acetate and [18F]FDG in cultured prostate cancer cells | Q40204286 | ||
| 11C-choline positron-emission tomography/computed tomography and transrectal ultrasonography for staging localized prostate cancer | Q40234547 | ||
| 18F-labeled bombesin analogs for targeting GRP receptor-expressing prostate cancer. | Q40309358 | ||
| Comparison of [14C]FMAU, [3H]FEAU, [14C]FIAU, and [3H]PCV for monitoring reporter gene expression of wild type and mutant herpes simplex virus type 1 thymidine kinase in cell culture | Q40393722 | ||
| The improved syntheses of 5-substituted 2'-[18F]fluoro-2'-deoxy-arabinofuranosyluracil derivatives ([18F]FAU, [18F]FEAU, [18F]FFAU, [18F]FCAU, [18F]FBAU and [18F]FIAU) using a multistep one-pot strategy. | Q46003497 | ||
| Automated synthesis of 2'-deoxy-2'-[18F]fluoro-5-methyl-1-β-D-arabinofuranosyluracil ([18F]-FMAU) using a one reactor radiosynthesis module. | Q46005821 | ||
| Glucose metabolism of human prostate cancer mouse xenografts. | Q46006892 | ||
| 1-11C-acetate kinetics of prostate cancer. | Q46007946 | ||
| The use of F-18 choline PET in the assessment of bone metastases in prostate cancer: correlation with morphological changes on CT. | Q46072225 | ||
| Analysis of hypoxia-associated gene expression in prostate cancer: lysyl oxidase and glucose transporter-1 expression correlate with Gleason score | Q46237005 | ||
| In vivo uptake of [11C]choline does not correlate with cell proliferation in human prostate cancer | Q46375907 | ||
| In vivo measurement of cell proliferation in canine brain tumor using C-11-labeled FMAU and PET. | Q46539928 | ||
| 2-[18F]fluoro-2-deoxyglucose positron emission tomography for the detection of disease in patients with prostate-specific antigen relapse after radical prostatectomy | Q46586622 | ||
| Prostate cancer: a comparative study of 11C-choline PET and MR imaging combined with proton MR spectroscopy | Q46625079 | ||
| Role of whole-body 18F-choline PET/CT in disease detection in patients with biochemical relapse after radical treatment for prostate cancer | Q46642656 | ||
| Synthesis of 2'-fluoro-5-[11C]-methyl-1-beta-D-arabinofuranosyluracil ([11C]-FMAU): a potential nucleoside analog for in vivo study of cellular proliferation with PET. | Q46701257 | ||
| PET imaging with 11C-acetate in prostate cancer: a biochemical, radiochemical and clinical perspective | Q46704395 | ||
| [Is 3'-deoxy-3'- [18F] fluorothymidine ([18F]-FLT) the next tracer for routine clinical PET after R [18F]-FDG?]. | Q46734878 | ||
| Detection and localization of prostate cancer: correlation of (11)C-choline PET/CT with histopathologic step-section analysis | Q46735738 | ||
| [(11)C]choline uptake with PET/CT for the initial diagnosis of prostate cancer: relation to PSA levels, tumour stage and anti-androgenic therapy | Q46804582 | ||
| 1-11C-acetate as a PET radiopharmaceutical for imaging fatty acid synthase expression in prostate cancer | Q46805035 | ||
| The value of 18F-choline PET/CT in patients with elevated PSA-level and negative prostate needle biopsy for localisation of prostate cancer | Q46813213 | ||
| Positron emission tomography/computed tomography with F-18-fluorocholine for restaging of prostate cancer patients: meaningful at PSA < 5 ng/ml? | Q46825545 | ||
| Evaluation of 2'-deoxy-2'-[18F]fluoro-5-methyl-1-beta-L: -arabinofuranosyluracil ([18F]-L: -FMAU) as a PET imaging agent for cellular proliferation: comparison with [18F]-D: -FMAU and [18F]FLT. | Q46867338 | ||
| The detection rate of [11C]choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. | Q46984864 | ||
| Kinetic analysis of 2-[11C]thymidine PET imaging studies: validation studies. | Q48232917 | ||
| Non-invasive evaluation of tumour hypoxia in the Shionogi tumour model for prostate cancer with 18F-EF5 and positron emission tomography. | Q50696506 | ||
| The sensitivity of [11C]choline PET/CT to localize prostate cancer depends on the tumor configuration. | Q51578822 | ||
| PET imaging of prostate cancer xenografts with a highly specific antibody against the prostate-specific membrane antigen. | Q51766972 | ||
| Kinetic analysis of 2-[carbon-11]thymidine PET imaging studies: compartmental model and mathematical analysis. | Q52241554 | ||
| Relationship between PSA kinetics and [18F]fluorocholine PET/CT detection rates of recurrence in patients with prostate cancer after total prostatectomy. | Q53191334 | ||
| Evaluation of primary prostate cancer using 11C-methionine-PET/CT and 18F-FDG-PET/CT. | Q53192471 | ||
| Use of [11C]choline PET-CT as a noninvasive method for detecting pelvic lymph node status from prostate cancer and relationship with choline kinase expression. | Q53194256 | ||
| Fluorocholine (18F) and sodium fluoride (18F) PET/CT in the detection of prostate cancer: prospective comparison of diagnostic performance determined by masked reading. | Q53215000 | ||
| The potential of FDG-PET/CT for detecting prostate cancer in patients with an elevated serum PSA level | Q53267697 | ||
| [(18)F]Fluoroacetate is not a functional analogue of [(11)C]acetate in normal physiology. | Q53358001 | ||
| Molecular imaging of prostate cancer. | Q53359744 | ||
| Comparison of 11C-choline-PET/CT and whole body-MRI for staging of prostate cancer. | Q53458930 | ||
| Tumor imaging using 1-(2'-deoxy-2'-18F-fluoro-beta-D-arabinofuranosyl)thymine and PET. | Q53465629 | ||
| Prostate cancer: sextant localization with MR imaging, MR spectroscopy, and 11C-choline PET/CT. | Q53471521 | ||
| 18F-fluoroacetate: a potential acetate analog for prostate tumor imaging--in vivo evaluation of 18F-fluoroacetate versus 11C-acetate. | Q53496838 | ||
| 11C-choline positron emission tomography/computerized tomography for tumor localization of primary prostate cancer in comparison with 12-core biopsy. | Q53525770 | ||
| Synthesis and biological evaluation of a fluorine-18-labeled nonsteroidal androgen receptor antagonist, N-(3-[18F]fluoro-4-nitronaphthyl)-cis-5-norbornene-endo-2,3-dicarboxylic imide. | Q53529221 | ||
| Flare response in 18F-fluoride ion PET bone scanning. | Q53537219 | ||
| Comparative in vitro and in vivo evaluation of two 64Cu-labeled bombesin analogs in a mouse model of human prostate adenocarcinoma. | Q53541731 | ||
| The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. | Q53553364 | ||
| MicroPET imaging of a gastrin-releasing peptide receptor-positive tumor in a mouse model of human prostate cancer using a 64Cu-labeled bombesin analogue. | Q53647143 | ||
| Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. | Q54117465 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | prostate cancer | Q181257 |
| P304 | page(s) | 278-291 | |
| P577 | publication date | 2012-08-01 | |
| P1433 | published in | American Journal of Roentgenology | Q15752879 |
| P1476 | title | Molecular imaging of prostate cancer: PET radiotracers | |
| P478 | volume | 199 |
| Q48191350 | (11)C-methylaminoisobutyric acid (MeAIB) PET for evaluation of prostate cancer: compared with (18)F-fluorodeoxyglucose PET. |
| Q36502692 | (18)F-fluorodeoxyglucose PET/CT for detection of disease in patients with prostate-specific antigen relapse following radical treatment of a local-stage prostate cancer |
| Q91617685 | A review of prostate cancer imaging, positron emission tomography, and radiopharmaceutical-based therapy |
| Q41008780 | An Assessment of Early Response to Targeted Therapy via Molecular Imaging: A Pilot Study of 3'-deoxy-3'[(18)F]-Fluorothymidine Positron Emission Tomography 18F-FLT PET/CT in Prostate Adenocarcinoma |
| Q34717742 | Applications of immunoPET: using 124I-anti-PSCA A11 minibody for imaging disease progression and response to therapy in mouse xenograft models of prostate cancer |
| Q37199286 | Baseline 18F-FDG PET/CT parameters as imaging biomarkers of overall survival in castrate-resistant metastatic prostate cancer. |
| Q34681161 | Bone metastases in castration-resistant prostate cancer: associations between morphologic CT patterns, glycolytic activity, and androgen receptor expression on PET and overall survival |
| Q43440505 | CCAFU Recommendations 2013: Prostate cancer |
| Q34228828 | Comparative performance of PET tracers in biochemical recurrence of prostate cancer: a critical analysis of literature. |
| Q90481802 | Comparative prognostic implication of treatment response assessments in mCRPC: PERCIST 1.0, RECIST 1.1, and PSA response criteria |
| Q98154721 | Comparison of prostate-specific membrane antigen ligands in clinical translation research for diagnosis of prostate cancer |
| Q37238715 | Competitive advantage of PET/MRI. |
| Q26825265 | Current Status of Hybrid PET/MRI in Oncologic Imaging |
| Q51803631 | Development of a Single Vial Kit Solution for Radiolabeling of 68Ga-DKFZ-PSMA-11 and Its Performance in Prostate Cancer Patients. |
| Q50721465 | Diagnosis of recurrent prostate cancer with PET/CT imaging using the gastrin-releasing peptide receptor antagonist 68Ga-RM2: Preliminary results in patients with negative or inconclusive [18F]Fluoroethylcholine-PET/CT. |
| Q33601455 | Effect of Androgen on Normal Biodistribution of [18F]-2'-Fluoro-5-methyl-1-beta-D-arabinofuranosyluracil (18F-FMAU) in Athymic Non-tumor-bearing Male Mice |
| Q28066696 | Imaging Cellular Proliferation in Prostate Cancer with Positron Emission Tomography |
| Q34035683 | Imaging evaluation of prostate cancer with 18F-fluorodeoxyglucose PET/CT: utility and limitations |
| Q39003083 | Is There Use for FDG-PET in Prostate Cancer? |
| Q49921472 | Metabolic Vulnerabilities of Prostate Cancer: Diagnostic and Therapeutic Opportunities |
| Q39438297 | Multimodal Imaging in Focal Therapy Planning and Assessment in Primary Prostate Cancer |
| Q38767020 | NMR-based metabolomics of prostate cancer: a protagonist in clinical diagnostics |
| Q36023165 | Nanoparticle-Enabled Selective Destruction of Prostate Tumor Using MRI-Guided Focal Photothermal Therapy |
| Q38616392 | New prospects for PET in prostate cancer imaging: a physicist's viewpoint. |
| Q38606252 | Novel Imaging of Prostate Cancer with MRI, MRI/US, and PET. |
| Q34068083 | Optimization of the preparation of fluorine-18-labeled steroid receptor ligands 16alpha-[18F]fluoroestradiol (FES), [18F]fluoro furanyl norprogesterone (FFNP), and 16beta-[18F]fluoro-5alpha-dihydrotestosterone (FDHT) as radiopharmaceuticals |
| Q39004440 | PET imaging of prostate tumors with 18F-Al-NOTA-MATBBN. |
| Q33890153 | Positron emission tomography (PET) in primary prostate cancer staging and risk assessment |
| Q33625371 | Positron emission tomography in imaging evaluation of staging, restaging, treatment response, and prognosis in prostate cancer |
| Q52983334 | Preclinical Evaluation of an Anti-Nectin-4 ImmunoPET Reagent in Tumor-Bearing Mice and Biodistribution Studies in Cynomolgus Monkeys. |
| Q92707314 | Prediction of Time to Hormonal Treatment Failure in Metastatic Castration-Sensitive Prostate Cancer with 18F-FDG PET/CT |
| Q35244433 | Prognostic Utility of PET in Prostate Cancer. |
| Q90264578 | Prospective Study of the Radiolabeled GRPR Antagonist BAY86-7548 for Positron Emission Tomography/Computed Tomography Imaging of Newly Diagnosed Prostate Cancer |
| Q38842687 | Prostate cancer imaging of FSHR antagonist modified with a hydrophilic linker |
| Q41548893 | Quantitative graphical analysis of simultaneous dynamic PET/MRI for assessment of prostate cancer. |
| Q38167022 | Strategies for imaging androgen receptor signaling pathway in prostate cancer: implications for hormonal manipulation and radiation treatment |
| Q36504085 | The combination of 13N-ammonia and 18F-FDG whole-body PET/CT on the same day for diagnosis of advanced prostate cancer |
| Q38987271 | The feasibility of assessing branched-chain amino acid metabolism in cellular models of prostate cancer with hyperpolarized [1-(13)C]-ketoisocaproate |
| Q38666376 | Ultrasound Elastography of the Prostate Using an Unconstrained Modulus Reconstruction Technique: A Pilot Clinical Study |
| Q52960162 | Usefulness of MRI-assisted metabolic volumetric parameters provided by simultaneous (18)F-fluorocholine PET/MRI for primary prostate cancer characterization. |
| Q53094162 | Writing PET into existence. |
Search more.